<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="230">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00901524</url>
  </required_header>
  <id_info>
    <org_study_id>2008-000859-10</org_study_id>
    <secondary_id>ANRS HC 20</secondary_id>
    <nct_id>NCT00901524</nct_id>
  </id_info>
  <brief_title>ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV</brief_title>
  <acronym>ETOC</acronym>
  <official_title>ANRS HC20 Pilot Study, Multicenter, Assessing the Effectiveness of an Optimized Anti HCV (360μg/Week Induction of PegIFN-alpha2a + 18mg/kg/j of RBV for 6 Months and Then Depending on the Virological Response to S12, Elongation up S72 to the Dual Anti HCV, With Accompanying Measures) on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effectiveness of an optimized anti HCV treatment
      (360μg per week of PegIFN-alpha2a + 18mg/kg/j of Ribavirin for 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients HIV infected, the success rate do not exceed 20% in genotype 1 or 4 patients. In
      case of treatment failure , patients are rarely re-treated, and liver fibrosis progresses
      rapidly. The new molecules are not yet available for patients co-infected with HIV, and
      patients having already undergone a first treatment will likely be among the last to be
      included in trials evaluating the effectiveness of these treatments.

      However, recent studies show that it is possible to propose a new treatment &quot;optimized&quot; to
      these patients in the hope to obtain better success rate. Provide antiretroviral treatment,
      use of high doses of Peg-interferon and ribavrine, and supporting patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Study the proportion of patients co-infected HIV-HCV, non-responders to treatment for HCV (genotype 1 and 4), with a sustained virological response (6 months after stopping treatment (W72 or W96)) at a re-optimized treatment of hepatitis C.</measure>
    <time_frame>W72 or W96 (depending of the end of treatment)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analyze rapid virological response (W4) and early (W12).</measure>
    <time_frame>W4 and W12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Hepatitis</condition>
  <arm_group>
    <arm_group_label>PegIFN- alpha 2a + RBV</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg-interféron alpha 2a + ribavirin</intervention_name>
    <description>Pilot study, multicenter, open label</description>
    <arm_group_label>PegIFN- alpha 2a + RBV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years

          -  Weight 85 kg below the pre-inclusion visit.

          -  Documented HIV infection (HIV positive)

          -  HCV infection documented by a positive PCR

          -  HCV Genotype 1 or 4

          -  Compensated liver disease (Child-Pugh below/equal to 6)

          -  Lymphocytes CD4 above 200/mm3

          -  Patient not answering a treatment for hepatitis C.

          -  Patient not covered by dual by Peg-IFN + riba for at least three months (wash out)

        Exclusion Criteria:

          -  Co-infection with HBV (HBsAg positive)

          -  Neutropenia below 1000/mm3

          -  Thrombocytopenia below 90000/mm3 or thrombocytosis over 500 000/mm3.

          -  Hemoglobin below 11 g / dL (men and women)

          -  Arguments radiological (ultrasound, CT or MRI) of hepatocellular carcinoma cell

          -  Antiretroviral containing didanosine (ddI) and stavudine (d4T) and zidovudine (AZT)
             and abacavir (ABC).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe BONNARD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Tenon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Tenon Service des Maladies Infectieuses</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.anrs.fr</url>
    <description>French National Agency for Research on AIDS and Viral Hepatitis website</description>
  </link>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>March 28, 2013</lastchanged_date>
  <firstreceived_date>April 28, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV Genotype 1, 4</keyword>
  <keyword>Virological response</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>PegPegIFN- alpha 2a</keyword>
  <keyword>Viral Hepatitis (HCV)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
